APA (7th ed.) Citation

Wollenberg, A., Ikeda, M., Chu, C., Eichenfield, L. F., Seyger, M. M. B., Prakash, A., . . . Paller, A. S. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: A randomized clinical trial of extended treatment to 3.6 years. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Wollenberg, Andreas, et al. Longer-term Safety and Efficacy of Baricitinib for Atopic Dermatitis in Pediatric Patients 2 to <18 Years Old: A Randomized Clinical Trial of Extended Treatment to 3.6 Years. Taylor & Francis Group.

MLA (9th ed.) Citation

Wollenberg, Andreas, et al. Longer-term Safety and Efficacy of Baricitinib for Atopic Dermatitis in Pediatric Patients 2 to <18 Years Old: A Randomized Clinical Trial of Extended Treatment to 3.6 Years. Taylor & Francis Group.